Sugi Predict
/ Targets
/ PARP14
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to PARP14 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation |
PHASE4 | ACTIVE_NOT_RECRUITING |
| Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients |
PHASE3 | COMPLETED |
| Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) |
PHASE2 | RECRUITING |
| Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) |
PHASE1/PHASE2 | COMPLETED |
| A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib |
PHASE2 | COMPLETED |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies |
PHASE1/PHASE2 | RECRUITING |
| A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer |
PHASE2 | COMPLETED |
| Trial of Maintenance With Niraparib- Uterine Serous Carcinoma |
PHASE2 | COMPLETED |
| Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Olaparib In Metastatic Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Phase II ABT-888 With Cyclophosphamide |
PHASE2 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas |
PHASE1 | COMPLETED |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer |
PHASE1 | UNKNOWN |
| ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer |
PHASE1 | COMPLETED |
| Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults |
PHASE1 | RECRUITING |
| AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers |
PHASE1 | COMPLETED |
| Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors |
PHASE1 | COMPLETED |
| Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Pre-Operative Radiation and Veliparib for Breast Cancer |
PHASE1 | COMPLETED |
| Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts |
PHASE1 | ACTIVE_NOT_RECRUITING |
| ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors |
PHASE1 | WITHDRAWN |
| PET Imaging of PARP Activity in Cancer |
EARLY_PHASE1 | UNKNOWN |
| Sirtuin1 in COVID19 Patients |
nan | UNKNOWN |
| Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer |
nan | NO_LONGER_AVAILABLE |
| Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a PARP14 binder may also engage these)